<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMBENONIUM CHLORIDE</span><br/>(am-be-noe'nee-um)<br/><span class="topboxtradename">Mytelase<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification"> cholinergic (parasympathomimetic)</span>; <span class="classification">cholinesterase inhibitor</span><br/><b>Prototype: </b>Neostigmine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Indirect-acting and a slowly reversible cholinesterase inhibitor approximately six times more potent than neostigmine.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits destruction of acetylcholine (ACh) by cholinesterase, thereby prolonging effects of ACh (neurotransmitter) at postsynaptic
         receptor sites. Has direct stimulant effect on striated muscles.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment of myasthenia gravis for patients who cannot tolerate neostigmine bromide or pyridostigmine bromide
         because of bromide sensitivity. Has been used in conjunction with corticosteroids, ephedrine sulfate, and potassium chloride
         to increase muscle strength.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Intestinal or urinary tract obstruction; patients receiving mecamylamine. Safety during pregnancy (category C) and lactation
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Epilepsy, bradycardia, cardiac arrhythmias, recent coronary occlusion; bronchial asthma; hyperthyroidism; vagotonia; peptic
         ulcer, megacolon.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Myasthenia Gravis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.55 mg t.i.d. or q.i.d., may increase q12d to 5075 mg t.i.d. or q.i.d. if necessary<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.3 mg/kg/d in 34 divided doses, may need up to 1.5 mg/kg/d in 34 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to minimize adverse effects.</li>
<li>Schedule larger doses when patient experiences the most fatigue or muscle weakness; to improve ability to eat, give drug 3045
            min before meals.
         </li>
<li>Store at 15°30° C (59°86° F) unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Exaggerated cholinergic (muscarinic) effects; muscle cramps, headache, confusion, dizziness, incoordination, fasciculations,
      agitation, restlessness, muscle weakness, <span class="speceff-life">paralysis</span>, slurred speech, convulsions, <span class="speceff-life">respiratory depression</span>. <span class="typehead">CV:</span> Bradycardia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, abdominal cramps, excessive salivation. <span class="typehead">Special Senses:</span> Blurred vision, lacrimation. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Bronchospasm</span>, increased bronchial secretions, dyspnea. <span class="typehead">Other:</span> Diaphoresis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Demecarium</b> and other <span class="classification">cholinesterase inhibitors</span> possibly compound toxicity; <b>mecamylamine,</b>
<b>succinylcholine,</b>
<b>procainamide,</b>
<b>quinidine,</b>
<span class="classification">aminoglycosides</span> increase neuromuscular blocking effects with possibility of respiratory depression; atropine antagonizes effects of ambenonium. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract. <span class="typehead">Onset:</span> 2030 min. <span class="typehead">Duration:</span> 38 h. <span class="typehead">Metabolism:</span> Unknown. <span class="typehead">Elimination:</span> Unknown. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Therapeutic effect may not be apparent for several days after initiation of therapy.</li>
<li>Keep atropine sulfate immediately available to treat severe cholinergic reactions.</li>
<li>Monitor for S&amp;S of overdosage (muscle weakness within 1 h; headache, weakness of muscles of neck, chewing, and swallowing,
            increased salivation) and inadequate ventilation (unusual apprehension, restlessness, rapid pulse and respirations, rising
            BP).
         </li>
<li>Monitor vital signs during dosage adjustment periods.</li>
<li>
            							Note: Muscle weakness beginning 3 h or more after drug administration is probably due to underdosage or drug resistance.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Follow directions for taking this drug (see <small>ADMINISTRATION</small>).
         </li>
<li>Learn to recognize adverse effects, how to modify the doses accordingly, and when to take atropine.</li>
<li>
            							Note: During long-term therapy the drug may become ineffective; responsiveness usually returns when dosage is reduced or drug is
            withdrawn for several days.
            						
         </li>
<li>Carry medical identification indicating medical diagnosis and medication(s) being taken.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>